News

Video

Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

Author(s):

Meletios A. Dimopoulos, MD

DREAMM-8 (NCT04484623) is an ongoing, randomized, open-label, phase 3 study evaluating BPd vs PVd in patients with RRMM previously treated with ≥1 line of therapy including lenalidomide.

Related Videos
Jill Corre, PharmD, PhD
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Amrita Krishnan, MD, executive medical director, Hematology, director, Judy and Bernard Briskin Multiple Myeloma Center, professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Suzanne Lentzsch, MD, PhD
Justin Kaner, MD
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Rahul Banerjee, MD, FACP
Ajai Chari, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Binod Dhakal, MD
Related Content
Ashraf Z. Badros, MB, Ch
October 17th 2024

Daratumumab/Lenalidomide Maintenance Deepens Responses, Boosts MRD-Negativity Rates in Myeloma After ASCT

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Shyam A. Patel, MD, PhD, University of Massachusetts Chan Medical School
October 16th 2024

Donor Clonal Hematopoiesis May Predict Post-Transplant Relapse and Outcomes in Hematologic Malignancies

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Ahmed Hamdy, MD, chief executive officer, Vincerx
October 11th 2024

VIP943 Generates Early Complete Responses, Is Safe in Advanced CD123+ Hematologic Malignancies

Edmond Chan, MBChB, MD, EMEA of Johnson & Johnson
October 10th 2024

EU Approval Sought for D-VRd in Newly Diagnosed Myeloma